Medicine
Antiretroviral Therapy Simplification to Dual Regimens in HIV
Quick fact
For people who have been virally suppressed on a three-drug regimen for at least six months, switching to a two-drug regimen with dolutegravir and lamivudine can safely maintain viral suppression while reducing the risk of kidney and bone toxicity from tenofovir, a common third drug.
Why this is interesting
Most people with HIV take three drugs every day—but what if two could do the job just as well? Simplifying to a dual regimen is becoming a powerful way to reduce pill burden, side effects, and long-term toxicity.
Read the full explanation
Understanding Antiretroviral Therapy Simplification to Dual Regimens in HIV
To understand dual regimens, think of a lock and key. The virus needs to copy itself, and each drug blocks a different step in that copying process. Traditional therapy uses three keys to block three different steps, which makes it very hard for the virus to escape. A dual regimen uses only two keys, but the keys are extra strong—they fit so well that the lock can hardly be picked. The idea is that if the virus can't make copies of itself, it can't mutate to become resistant. In clinical practice, this simplification is only offered to patients who have already achieved stable viral suppression—meaning the virus is undetectable in their blood—for at least six months. That's when doctors know the virus is already well-controlled, and a two-drug combo can keep it in check with fewer medications.
A deeper explanation
The mechanism behind dual regimens lies in the potency and barrier to resistance of the selected drugs. Dolutegravir, an integrase strand transfer inhibitor, works by blocking the virus from inserting its DNA into the host cell's genome. Lamivudine, a nucleoside reverse transcriptase inhibitor, stops the virus from building its DNA. Together they block two different stages of viral replication. Because dolutegravir has a very high genetic barrier to resistance—meaning the virus must undergo multiple mutations to evade it—the dual regimen remains effective even if the virus tries to mutate. Additionally, simplifying ART reduces long-term toxicity: for example, tenofovir, often used as a third drug, can damage the kidneys and reduce bone density. By removing it, dual regimens improve bone and kidney health, while also lowering cost and pill burden. However, simplification is not for everyone; it requires evidence of good adherence and no prior history of resistance to the drugs used. This careful patient selection—plus the strategic choice of potent, well-tolerated drugs—is what makes dual therapy a safe and effective option in the modern era of HIV care.